John Robertson, MD
Plastic and Reconstructive Surgery · Montgomery, ALNPI 1841250156
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 61.4% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $1,089 and has fallen 55.5% since, to $484 in 2025.
Across 176 payments — averaging $26.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Mentor Worldwide LLC$411
- Merz North America, Inc.$409
- Sientra, Inc.$362
- Integra Lifesciences Corporation$208
- Regeneron Healthcare Solutions, Inc.$84
- plus $342 from 13 others
Across 2 payments — averaging $1925.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sientra, Inc.$4K
What the payments were for
- Food & beverage$4,61498%
- Education$932%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 116 | $2,891 |
| Mentor Worldwide LLC | 23 | $411 |
| Merz North America, Inc. | 7 | $409 |
| Sientra, Inc. | 7 | $362 |
| Integra Lifesciences Corporation | 4 | $208 |
| Regeneron Healthcare Solutions, Inc. | 3 | $84 |
| Aerin Medical Inc. | 1 | $57 |
| TEI Biosciences Inc | 2 | $55 |
| Vertex | 2 | $44 |
| TELA Bio, Inc. | 2 | $34 |
| Motiva USA, LLC | 1 | $22 |
| Revance Therapeutics, Inc. | 1 | $20 |
| Vioptix Inc | 1 | $19 |
| Mimedx Group, Inc. | 1 | $19 |
| Heron Therapeutics, Inc. | 1 | $17 |
| Avanos Medical | 1 | $15 |
| Galderma Laboratories, L.p. | 1 | $15 |
| Smith+Nephew | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,707 in reported general payments places this provider in the 75th percentile of 35 plastic and reconstructive surgery providers in Alabama.
See all plastic and reconstructive surgery providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 16 | $86 |
Paid to pharmacies, not to this prescriber.
Other plastic and reconstructive surgery in Montgomery
- Michael BentleyMontgomery$5K
- Robert BollingTuscaloosa$71K
- Brad DenneyBirmingham$21K
- Tony WeaverHuntsville$13K
- Michael BeckensteinBirmingham$10K
- Jeffery WaldingDothan$10K
- Robert OliverBirmingham$7K
- Paul SauerBirmingham$6K
- Jonathan AntonettiBirmingham$4K
- Robert KnowlingHuntsville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.